Shares

7 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Nov 14, 2022

SELL
$0.78 - $8.9 $794,169 - $9.06 Million
-1,018,166 Reduced 53.6%
881,450 $5.68 Million
Q1 2022

May 16, 2022

SELL
$1.02 - $3.8 $295,374 - $1.1 Million
-289,583 Reduced 13.23%
1,899,616 $2.26 Million
Q4 2020

Feb 17, 2021

BUY
$6.66 - $14.66 $5.2 Million - $11.5 Million
781,250 Added 55.49%
2,189,199 $23.8 Million
Q3 2020

Nov 16, 2020

SELL
$8.69 - $14.47 $1.42 Million - $2.37 Million
-163,954 Reduced 10.43%
1,407,949 $11.6 Million
Q2 2020

Aug 14, 2020

SELL
$5.21 - $11.03 $805,987 - $1.71 Million
-154,700 Reduced 8.96%
1,571,903 $15.9 Million
Q2 2019

Aug 14, 2019

BUY
$5.5 - $9.75 $3.67 Million - $6.5 Million
666,665 Added 62.9%
1,726,603 $15.2 Million
Q4 2018

Feb 14, 2019

BUY
$5.55 - $11.34 $5.88 Million - $12 Million
1,059,938 New
1,059,938 $5.9 Million

About Syros Pharmaceuticals, Inc.


  • Ticker SYRS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 20,236,200
  • Market Cap $4.86M
  • Description
  • Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatments for cancer and monogenic diseases, and building a pipeline of gene control medicines. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically def...
More about SYRS
Track This Portfolio

Track Samsara Bio Capital, LLC Portfolio

Follow Samsara Bio Capital, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Samsara Bio Capital, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Samsara Bio Capital, LLC with notifications on news.